Clinical Trial ResultsPositive vocal biomarker data reported from a prior P3 study indicates brilaroxazine's potential to improve negative symptoms of schizophrenia, addressing an unmet need as current therapies target positive symptoms.
Market ReactionRVPH shares have increased by approximately 30%, attributed to the OLE data and recent developments with competitors.
Regulatory ProgressThe company is preparing for its second P3 study, which could potentially position the company for NDA submission for brilaroxazine in schizophrenia.